CN111902428A - 一种双特异性抗体及其用途 - Google Patents
一种双特异性抗体及其用途 Download PDFInfo
- Publication number
- CN111902428A CN111902428A CN201980019463.3A CN201980019463A CN111902428A CN 111902428 A CN111902428 A CN 111902428A CN 201980019463 A CN201980019463 A CN 201980019463A CN 111902428 A CN111902428 A CN 111902428A
- Authority
- CN
- China
- Prior art keywords
- antibody
- heavy chain
- seq
- chain variable
- tim
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims abstract description 186
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims abstract description 161
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims abstract description 154
- 230000027455 binding Effects 0.000 claims abstract description 113
- 230000000694 effects Effects 0.000 claims abstract description 86
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 67
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 66
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims abstract description 55
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 36
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 32
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 28
- 102000049109 human HAVCR2 Human genes 0.000 claims abstract description 27
- 241001515942 marmosets Species 0.000 claims abstract description 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 18
- 230000003213 activating effect Effects 0.000 claims abstract description 18
- 230000002147 killing effect Effects 0.000 claims abstract description 18
- 241000282553 Macaca Species 0.000 claims abstract description 14
- 108020001580 protein domains Proteins 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 48
- 150000001413 amino acids Chemical group 0.000 claims description 41
- 108060003951 Immunoglobulin Proteins 0.000 claims description 35
- 102000018358 immunoglobulin Human genes 0.000 claims description 35
- 239000000427 antigen Substances 0.000 claims description 32
- 102000036639 antigens Human genes 0.000 claims description 31
- 108091007433 antigens Proteins 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 25
- 210000004899 c-terminal region Anatomy 0.000 claims description 24
- 239000000872 buffer Substances 0.000 claims description 23
- 229940079593 drug Drugs 0.000 claims description 23
- 238000002965 ELISA Methods 0.000 claims description 22
- 229960002885 histidine Drugs 0.000 claims description 17
- 230000000903 blocking effect Effects 0.000 claims description 16
- 229940024606 amino acid Drugs 0.000 claims description 15
- 230000008685 targeting Effects 0.000 claims description 15
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 10
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 9
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 9
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 9
- 229920000053 polysorbate 80 Polymers 0.000 claims description 9
- 229960002621 pembrolizumab Drugs 0.000 claims description 8
- 239000007853 buffer solution Substances 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229960003301 nivolumab Drugs 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 206010062016 Immunosuppression Diseases 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 230000001506 immunosuppresive effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 3
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 3
- 102100037850 Interferon gamma Human genes 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 241000282567 Macaca fascicularis Species 0.000 claims description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 53
- 238000000034 method Methods 0.000 description 37
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 33
- 238000013461 design Methods 0.000 description 32
- 238000011156 evaluation Methods 0.000 description 22
- 239000000523 sample Substances 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 18
- 239000013641 positive control Substances 0.000 description 18
- 238000004925 denaturation Methods 0.000 description 16
- 230000036425 denaturation Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 108010076504 Protein Sorting Signals Proteins 0.000 description 13
- 239000012537 formulation buffer Substances 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 11
- 230000022534 cell killing Effects 0.000 description 11
- 210000004443 dendritic cell Anatomy 0.000 description 11
- 210000004408 hybridoma Anatomy 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 230000009977 dual effect Effects 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 238000001502 gel electrophoresis Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000005457 optimization Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 101100075830 Caenorhabditis elegans mab-5 gene Proteins 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 6
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000003593 chromogenic compound Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 102000048362 human PDCD1 Human genes 0.000 description 6
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
- 101150046249 Havcr2 gene Proteins 0.000 description 4
- 101001037141 Homo sapiens Immunoglobulin heavy variable 3-21 Proteins 0.000 description 4
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 4
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 4
- 102100040217 Immunoglobulin heavy variable 3-21 Human genes 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 101000839662 Homo sapiens Immunoglobulin heavy variable 3-48 Proteins 0.000 description 3
- 101001037153 Homo sapiens Immunoglobulin heavy variable 3-7 Proteins 0.000 description 3
- 101001138089 Homo sapiens Immunoglobulin kappa variable 1-39 Proteins 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 102100028320 Immunoglobulin heavy variable 3-48 Human genes 0.000 description 3
- 102100040231 Immunoglobulin heavy variable 3-7 Human genes 0.000 description 3
- 102100020910 Immunoglobulin kappa variable 1-39 Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003118 sandwich ELISA Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 244000298715 Actinidia chinensis Species 0.000 description 2
- 235000009434 Actinidia chinensis Nutrition 0.000 description 2
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102100031351 Galectin-9 Human genes 0.000 description 2
- 101710121810 Galectin-9 Proteins 0.000 description 2
- 101001138128 Homo sapiens Immunoglobulin kappa variable 1-12 Proteins 0.000 description 2
- 102100020773 Immunoglobulin kappa variable 1-12 Human genes 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 101150030213 Lag3 gene Proteins 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 229940126546 immune checkpoint molecule Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- -1 3-methylenepropyl Chemical group 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000012739 FreeStyle 293 Expression medium Substances 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108700010013 HMGB1 Proteins 0.000 description 1
- 101150021904 HMGB1 gene Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100037907 High mobility group protein B1 Human genes 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- 101001138125 Homo sapiens Immunoglobulin kappa variable 1-17 Proteins 0.000 description 1
- 101001138123 Homo sapiens Immunoglobulin kappa variable 1-27 Proteins 0.000 description 1
- 101001138132 Homo sapiens Immunoglobulin kappa variable 1-6 Proteins 0.000 description 1
- 101001008259 Homo sapiens Immunoglobulin kappa variable 1D-12 Proteins 0.000 description 1
- 101001008313 Homo sapiens Immunoglobulin kappa variable 1D-39 Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102100020945 Immunoglobulin kappa variable 1-17 Human genes 0.000 description 1
- 102100020902 Immunoglobulin kappa variable 1-27 Human genes 0.000 description 1
- 102100020768 Immunoglobulin kappa variable 1-6 Human genes 0.000 description 1
- 102100027412 Immunoglobulin kappa variable 1D-12 Human genes 0.000 description 1
- 102100027404 Immunoglobulin kappa variable 1D-39 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000037843 metastatic solid tumor Diseases 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000013365 molecular weight analysis method Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000012945 sealing adhesive Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000009792 yinqiao Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70521—CD28, CD152
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供了一种双特异性抗体及其用途。所述双特异性抗体包含第一蛋白功能区和第二蛋白功能区，其中，第一蛋白功能区靶向TIM‑3，其对应的靶向TIM‑3的TIM‑3全长抗体与猕猴(Macaca)TIM‑3有弱结合活性，与狨猴(Marmoset)和人TIM‑3有强结合活性并能够激活人NK细胞对肿瘤细胞的杀伤作用。所述的双特异性抗体保留单个TIM‑3抗体所具有的激活PBMC(NK)杀伤肿瘤细胞的活性，同时保持另一个蛋白功能区的原有活性，并能够达到和两个分子联用相当或者更好激活T淋巴细胞的活性。
Description
PCT国内申请，说明书已公开。
Claims (16)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810720048 | 2018-07-03 | ||
| CN2018107200488 | 2018-07-03 | ||
| PCT/CN2019/093548 WO2020007240A1 (zh) | 2018-07-03 | 2019-06-28 | 一种双特异性抗体及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111902428A true CN111902428A (zh) | 2020-11-06 |
| CN111902428B CN111902428B (zh) | 2023-11-10 |
Family
ID=69059466
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980019463.3A Active CN111902428B (zh) | 2018-07-03 | 2019-06-28 | 一种双特异性抗体及其用途 |
| CN201910576333.1A Active CN110669135B (zh) | 2018-07-03 | 2019-06-28 | 一种双特异性抗体及其用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910576333.1A Active CN110669135B (zh) | 2018-07-03 | 2019-06-28 | 一种双特异性抗体及其用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210269521A1 (zh) |
| EP (1) | EP3819313A4 (zh) |
| JP (1) | JP7352973B2 (zh) |
| CN (2) | CN111902428B (zh) |
| WO (1) | WO2020007240A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111518214B (zh) * | 2019-02-03 | 2023-09-22 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的双特异性抗体及其制备方法和应用 |
| CN113150150B (zh) * | 2020-02-24 | 2023-08-11 | 苏州恒康生命科学有限公司 | Tim3结合分子及其应用 |
| CN113698478A (zh) * | 2020-05-21 | 2021-11-26 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其稳定制剂 |
| WO2022002038A1 (zh) * | 2020-06-30 | 2022-01-06 | 和铂医药(上海)有限责任公司 | 免疫细胞衔接器多特异性结合蛋白及其制备和应用 |
| CN111748040B (zh) * | 2020-07-31 | 2021-09-28 | 杭州皓阳生物技术有限公司 | 多价抗体及其制备方法 |
| CN113603779B (zh) * | 2021-08-18 | 2023-06-02 | 深圳市元谷生物科技有限公司 | 一种结合人淋巴细胞活化基因3(lag-3)的抗体及其用途 |
| CN115246885B (zh) * | 2022-06-30 | 2023-10-24 | 盛禾(中国)生物制药有限公司 | 一种双特异性抗体及其应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016015685A1 (zh) * | 2014-07-30 | 2016-02-04 | 珠海市丽珠单抗生物技术有限公司 | 抗pd-1抗体及其应用 |
| WO2016071448A1 (en) * | 2014-11-06 | 2016-05-12 | F. Hoffmann-La Roche Ag | Anti-tim3 antibodies and methods of use |
| WO2017055404A1 (en) * | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
| WO2017087547A1 (en) * | 2015-11-17 | 2017-05-26 | Oncomed Pharmaceuticals, Inc. | Pd-l1-binding agents and uses thereof |
| CN108948193A (zh) * | 2017-05-18 | 2018-12-07 | 珠海市丽珠单抗生物技术有限公司 | 针对tim-3的抗体分子,抗原结合片段及其医药用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201840336A (zh) | 2011-08-01 | 2018-11-16 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| US10465014B2 (en) * | 2016-03-04 | 2019-11-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | PDL-1 antibody, pharmaceutical composition thereof, and uses thereof |
| CN107459578B (zh) * | 2016-05-31 | 2021-11-26 | 泰州迈博太科药业有限公司 | 一种靶向cd47与pd-l1的双功能融合蛋白 |
| JOP20190133A1 (ar) * | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1 |
| CN106986939B (zh) * | 2017-03-27 | 2019-06-07 | 顺昊细胞生物技术（天津）股份有限公司 | 抗pd-1和tem-8双特异性抗体及其应用 |
| US20220281997A1 (en) * | 2019-09-27 | 2022-09-08 | Nanjing GenScript Biotech Co., Ltd. | Anti-VHH Domain Antibodies and Use Thereof |
-
2019
- 2019-06-28 WO PCT/CN2019/093548 patent/WO2020007240A1/zh unknown
- 2019-06-28 JP JP2020573186A patent/JP7352973B2/ja active Active
- 2019-06-28 CN CN201980019463.3A patent/CN111902428B/zh active Active
- 2019-06-28 CN CN201910576333.1A patent/CN110669135B/zh active Active
- 2019-06-28 EP EP19831370.2A patent/EP3819313A4/en active Pending
- 2019-06-28 US US17/254,862 patent/US20210269521A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016015685A1 (zh) * | 2014-07-30 | 2016-02-04 | 珠海市丽珠单抗生物技术有限公司 | 抗pd-1抗体及其应用 |
| WO2016071448A1 (en) * | 2014-11-06 | 2016-05-12 | F. Hoffmann-La Roche Ag | Anti-tim3 antibodies and methods of use |
| WO2017055404A1 (en) * | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
| WO2017087547A1 (en) * | 2015-11-17 | 2017-05-26 | Oncomed Pharmaceuticals, Inc. | Pd-l1-binding agents and uses thereof |
| CN108948193A (zh) * | 2017-05-18 | 2018-12-07 | 珠海市丽珠单抗生物技术有限公司 | 针对tim-3的抗体分子,抗原结合片段及其医药用途 |
Non-Patent Citations (1)
| Title |
|---|
| 马琳琳等: "TIM-3纳米抗体噬菌体展示文库的构建及筛选" * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3819313A1 (en) | 2021-05-12 |
| CN110669135A (zh) | 2020-01-10 |
| JP2021530207A (ja) | 2021-11-11 |
| WO2020007240A1 (zh) | 2020-01-09 |
| EP3819313A4 (en) | 2021-09-01 |
| US20210269521A1 (en) | 2021-09-02 |
| CN111902428B (zh) | 2023-11-10 |
| JP7352973B2 (ja) | 2023-09-29 |
| CN110669135B (zh) | 2022-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110669135B (zh) | 一种双特异性抗体及其用途 | |
| KR102662387B1 (ko) | B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도 | |
| Dimitrov | Therapeutic proteins | |
| CN110366560B (zh) | 抗b7-h4抗体、其抗原结合片段及其医药用途 | |
| JP2020504171A (ja) | 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| JP2023071876A (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| WO2019024911A1 (zh) | B7h3抗体-药物偶联物及其医药用途 | |
| WO2019141268A1 (zh) | 抗4-1bb抗体、其抗原结合片段及其医药用途 | |
| CN111744007A (zh) | 一种抗tigit抗体药物组合物及其用途 | |
| TW201414747A (zh) | Ｉｌ－１８結合分子 | |
| CN113330036B (zh) | 结合pd-l1和ox40的双特异性抗体 | |
| KR20190112299A (ko) | 결합제 | |
| WO2019184935A1 (zh) | 抗cd27抗体、其抗原结合片段及其医药用途 | |
| CN116323657B (zh) | 同时靶向PD-L1和TGFβ的双功能分子及其医药用途 | |
| TWI685504B (zh) | 抗gitr抗體、其抗原結合片段及其醫藥用途 | |
| WO2020249041A1 (zh) | 靶向lag-3的抗体和双特异性抗体及其用途 | |
| WO2021213245A1 (zh) | 抗体或其抗原结合片段、其制备方法及医药用途 | |
| CN114981301A (zh) | Pd1和vegfr2双结合剂 | |
| CN111788229A (zh) | Csf1r结合剂 | |
| CN116897053A (zh) | 含抗tslp抗体的药物组合物 | |
| WO2022116858A1 (zh) | 一种抗tslp抗体药物组合物及其用途 | |
| WO2023025249A1 (zh) | 一种含融合蛋白的药物组合物 | |
| WO2022127842A1 (zh) | 靶向il-17a和il-36r的双特异性抗体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |